勘误：葡萄膜炎中的肿瘤坏死因子-α：从实验室到临床
Corrigendum: TNF-α in Uveitis: From Bench to Clinic.
作者信息
Jiang Qi, Li Zhaohuai, Tao Tianyu, Duan Runping, Wang Xianggui, Su Wenru
机构信息
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.
Eye Center of Xiangya Hospital, Central South University, Changsha, China.
出版信息
Front Pharmacol. 2022 Feb 25;13:817235. doi: 10.3389/fphar.2022.817235. eCollection 2022.
Abstract
[This corrects the article DOI: 10.3389/fphar.2021.740057.].
摘要
[本文更正了文章的数字对象标识符：10.3389/fphar.2021.740057。]
相似文献
1
Corrigendum: TNF-α in Uveitis: From Bench to Clinic.勘误：葡萄膜炎中的肿瘤坏死因子-α：从实验室到临床
Front Pharmacol. 2022 Feb 25;13:817235. doi: 10.3389/fphar.2022.817235. eCollection 2022.
2
TNF-α in Uveitis: From Bench to Clinic.葡萄膜炎中的肿瘤坏死因子-α：从实验室到临床
Front Pharmacol. 2021 Nov 2;12:740057. doi: 10.3389/fphar.2021.740057. eCollection 2021.
3
The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α.经跨膜肿瘤坏死因子 α 介导的培塞利珠单抗和古塞库单抗的细胞毒性作用。
Inflamm Bowel Dis. 2013 May;19(6):1224-31. doi: 10.1097/MIB.0b013e318280b169.
4
Anti-tumor necrosis factor-α therapy in uveitis.肿瘤坏死因子-α治疗在葡萄膜炎中的应用
Surv Ophthalmol. 2015 Nov-Dec;60(6):575-89. doi: 10.1016/j.survophthal.2015.06.004. Epub 2015 Jul 9.
5
Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis.使用生物荧光成像比较赛妥珠单抗聚乙二醇化制剂、阿达木单抗和英夫利昔单抗在胶原诱导性关节炎小鼠炎症爪子中的分布。
J Immunol Methods. 2009 Aug 31;348(1-2):36-41. doi: 10.1016/j.jim.2009.06.009. Epub 2009 Jun 28.
6
Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults.英夫利昔单抗、阿达木单抗和戈利木单抗治疗成人非感染性难治性葡萄膜炎的有效性。
Int J Clin Pharmacol Ther. 2015 May;53(5):377-90. doi: 10.5414/CP202171.
7
Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.抗肿瘤坏死因子药物在初治克罗恩病患者中的疗效及安全性比较
Clin Gastroenterol Hepatol. 2016 Aug;14(8):1120-1129.e6. doi: 10.1016/j.cgh.2016.03.038. Epub 2016 Apr 4.
8
Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.专家小组关于在眼部炎症性疾病患者中使用抗肿瘤坏死因子生物制剂的建议。
Ophthalmology. 2014 Mar;121(3):785-96.e3. doi: 10.1016/j.ophtha.2013.09.048. Epub 2013 Dec 17.
9
[Research update of anti-TNF-α biologic agents in the treatment of uveitis].[抗TNF-α生物制剂治疗葡萄膜炎的研究进展]
Zhonghua Yan Ke Za Zhi. 2013 Mar;49(3):285-8.
10
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.用于维持克罗恩病缓解的肿瘤坏死因子-α抗体。
Cochrane Database Syst Rev. 2008 Jan 23(1):CD006893. doi: 10.1002/14651858.CD006893.
引用本文的文献
1
TNFα and IL-8 vitreous concentrations variations with two antidiabetic therapies in patients with proliferative diabetic retinopathy: an observational study.在增殖型糖尿病性视网膜病变患者中，两种抗糖尿病治疗方法对 TNFα 和 IL-8 玻璃体浓度的影响：一项观察性研究。
BMC Ophthalmol. 2024 Sep 9;24(1):399. doi: 10.1186/s12886-024-03659-4.
Zotero 插件